Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Papyrus Holding AB
Mandate

Vinge has advised Papyrus Holding AB

January 11, 2017

Vinge has advised Papyrus Holding AB in connection with its acquisition of Procurator AB from RoosGruppen AB. The Procurator-group is one of the leading suppliers of inter alia protective clothing and personal protective equipment and cleaning and hygiene products in Sweden, Finland, Norway, Denmark and Estonia. The company had revenues of approx. MEUR 120 in 2015. The transaction is subject to relevant approval from the Swedish Competition Authority.

Vinge´s team consisted of partners in charge Christina Kokko (M&A) and Anna Palmérus (competition law) and among others Kristina Ekberg, Oscar Rydén, Johanna Wiberg and Ilze Lukins (M&A), Frida Ställborn (competition law), Sara Strandberg and Lisa Sennerby (employment), Josefine Lanker (financing), Tomas Forsgren (IP), Nicklas Thorgerzon (IT), Kristoffer Larson (real estate), Jasmin Draszka-Ali (CSR) and Andréa Nicolin (agreements).

Related

Vinge advises OsteoCentric on the public offer for Integrum

 OsteoCentric Oncology and Bone Anchored Prostheses, LLC, a subsidiary of OsteoCentric Technologies, Inc., has made a public offer for all shares in Integrum AB (publ). The offer values all shares in Integrum at approximately SEK 939 million.
July 23, 2025

Vinge advises Investor on its co-investment in the SEK 55 billion public offer for Fortnox led by EQT X

 Vinge advises Investor AB (publ) (“Investor”) on its co-investment in the public offer for Fortnox AB (publ) (“Fortnox”) led by EQT X together with First Kraft AB (owned by Olof Hallrup), acting through Omega II AB (“Omega II”). Fortnox offers vital software infrastructure to small and medium-sized companies in Sweden with a track record of profitable growth.
July 22, 2025

Vinge advises Cantargia in connection with the sale of immunology program CAN10

 Vinge advises Cantargia AB (publ) in connection with the sale of its early-clinical stage IL1RAP immunology program CAN10 to the Japanese healthcare company Otsuka Pharmaceutical.
July 21, 2025